| Protein Name | BCL-XL (B-Cell Lymphoma-Extra Large) |
|---|
| Gene | [BCL2L1](/genes/bcl2l1) |
|---|
| UniProt ID | Q07817 |
|---|
| Protein Size | 233 amino acids (~30 kDa); alternative splicing generates BCL-XS (178 aa) |
|---|
| Subcellular Localization | Mitochondrial outer membrane; endoplasmic reticulum; nucleus |
|---|
| Protein Family | BCL-2 family (anti-apoptotic) |
|---|
| PDB Structures | 1LXL, 1R2D, 5AGW |
|---|
BCL-XL (BCL2L1) is a critical anti-apoptotic protein of the BCL-2 family that inhibits mitochondrial apoptosis by preventing mitochondrial outer membrane permeabilization (MOMP). It is a key regulator of neuronal survival and is implicated in various neurodegenerative diseases.
BCL-XL has the characteristic BCL-2 family fold:
- BH4 Domain (aa 1-24): Required for anti-apoptotic function
- BH3 Domain (aa 82-93): Critical for interaction with pro-apoptotic proteins
- BH1 Domain (aa 136-149): Forms part of the BH3-binding pocket
- BH2 Domain (aa 177-189): Contributes to oligomerization and function
- Transmembrane Domain (aa 210-230): Anchors protein to membranes
The protein forms a hydrophobic groove that binds the BH3 domains of pro-apoptotic proteins.
Alternative Splicing: BCL2L1 produces two major isoforms:
- BCL-XL (233 aa): Anti-apoptotic, inhibits apoptosis
- BCL-XS (178 aa): Pro-apoptotic, promotes cell death
BCL-XL performs essential anti-apoptotic functions:
-
Inhibition of MOMP: Prevents mitochondrial outer membrane permeabilization by sequestering BH3-only proteins and inhibiting BAX/BAK activation[1].
-
Mitochondrial Stability: Maintains mitochondrial integrity and prevents release of cytochrome c and other pro-apoptotic factors.
-
Regulation of Autophagy: Interacts with BECN1 to regulate autophagy; BCL-XL binds and inhibits BECN1.
-
Neuronal Development: Critical for development and survival of specific neuronal populations.
-
Synaptic Protection: Protects synapses from apoptotic-induced elimination during development.
- Neurons in AD show increased BCL-XL as a compensatory neuroprotective response
- However, BCL-XL function becomes impaired by interaction with other disease proteins
- Tau pathology affects BCL-XL localization and function
- BCL-XL protects dopaminergic neurons from various toxic insults
- Reduced BCL-XL in PD substantia nigra contributes to vulnerability
- MPTP and other PD toxins downregulate BCL-XL
- Mutant SOD1 directly interacts with BCL-XL, impairing its anti-apoptotic function
- BCL-XL levels correlate with motor neuron survival
- Targeting BCL-XL is being explored therapeutically
¶ Stroke and Brain Injury
- BCL-XL is neuroprotective in ischemic injury models
- Overexpression reduces infarct size in experimental stroke
- BCL-XL is frequently overexpressed in cancers (especially BCL-XL vs BCL-2)
- Major resistance factor against chemotherapy
- Target of BH3 mimetic drugs (e.g., Navitoclax)
BCL-XL is a major therapeutic target:
- BH3 Mimetics: Navitoclax (ABT-263), Venetoclax (ABT-199 - more BCL-2 selective), DT2216
- Direct Inhibitors: Small molecules that neutralize BCL-XL anti-apoptotic function
- Protein-Protein Interaction Blockers: Prevent BCL-XL from binding pro-apoptotic proteins
Important: BCL-XL inhibition can cause thrombocytopenia because platelets depend on BCL-XL for survival.
BCL-XL interacts with:
- BAX: Inhibits pro-apoptotic oligomerization
- BAK: Prevents activation
- BH3-only proteins: BIM, BAD, BID, PUMA, NOXA (sequesters them)
- BECN1: Inhibits autophagy
- Mutant SOD1: In ALS, binds and sequesters BCL-XL
- VDAC: Modulates mitochondrial permeability
- [1] BCL-XL structure and function (Muchmore et al., 1996)